Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), In Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available.

Trial Profile

Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), In Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs IMC CS4 (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 04 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
    • 04 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
    • 09 Jun 2017 Planned End Date changed from 1 May 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top